Metabolomics approach reveals effects of antihypertensives and lipid-lowering drugs on the human metabolism
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
The mechanism of antihypertensive and lipid-lowering drugs on the human organism is still not fully understood. New insights on the drugs' action can be provided by a metabolomics-driven approach, which offers a detailed view of the physiological state of an organism. Here, we report a metabolome-wide association study with 295 metabolites in human serum from 1,762 participants of the KORA F4 (Cooperative Health Research in the Region of Augsburg) study population. Our intent was to find variations of metabolite concentrations related to the intake of various drug classes and--based on the associations found--to generate new hypotheses about on-target as well as off-target effects of these drugs. In total, we found 41 significant associations for the drug classes investigated: For beta-blockers (11 associations), angiotensin-converting enzyme (ACE) inhibitors (four assoc.), diuretics (seven assoc.), statins (ten assoc.), and fibrates (nine assoc.) the top hits were pyroglutamine, phenylalanylphenylalanine, pseudouridine, 1-arachidonoylglycerophosphocholine, and 2-hydroxyisobutyrate, respectively. For beta-blockers we observed significant associations with metabolite concentrations that are indicative of drug side-effects, such as increased serotonin and decreased free fatty acid levels. Intake of ACE inhibitors and statins associated with metabolites that provide insight into the action of the drug itself on its target, such as an association of ACE inhibitors with des-Arg(9)-bradykinin and aspartylphenylalanine, a substrate and a product of the drug-inhibited ACE. The intake of statins which reduce blood cholesterol levels, resulted in changes in the concentration of metabolites of the biosynthesis as well as of the degradation of cholesterol. Fibrates showed the strongest association with 2-hydroxyisobutyrate which might be a breakdown product of fenofibrate and, thus, a possible marker for the degradation of this drug in the human organism. The analysis of diuretics showed a heterogeneous picture that is difficult to interpret. Taken together, our results provide a basis for a deeper functional understanding of the action and side-effects of antihypertensive and lipid-lowering drugs in the general population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.23.2981 · Cited by 5,664
Human metabolic individuality in biomedical and pharmaceutical research
CARDIoGRAM, Suhre, K., Shin, S.-Y., Petersen, A.-K., Mohney, R. P., Meredith, D., Wägele, B., Altmaier, E., Deloukas, P., Erdmann, J., et al. (2011) · Nature · doi:10.1038/nature10354 · Cited by 1,017 · cited 1×
“Our sampling population was composed of Caucasians of European ancestry, so these results cannot be generalized to other ethnicities—effects of genetic variation on metabolism needs to be considered [20, 61, 62].”
BackgroundSelf-citationHebert, P. R. (1997) · JAMA · doi:10.1001/jama.1997.03550040069040 · Cited by 740
Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum
Gieger, C., Geistlinger, L., Altmaier, E., Hrabé de Angelis, M., Kronenberg, F., Meitinger, T., Mewes, H.-W., Wichmann, H.-E., Weinberger, K. M., Adamski, J., et al. (2008) · PLoS Genetics · doi:10.1371/journal.pgen.1000282 · Cited by 737 · cited 1×
“Our sampling population was composed of Caucasians of European ancestry, so these results cannot be generalized to other ethnicities—effects of genetic variation on metabolism needs to be considered [20, 61, 62].”
BackgroundSelf-citationRelationship of plasma polyunsaturated fatty acids to circulating inflammatory markers.
Ferrucci, L., Cherubini, A., Bandinelli, S., Bartali, B., Corsi, A., Lauretani, F., Martin, A., Andres-Lacueva, C., Senin, U., & Guralnik, J. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1303 · Cited by 696 · cited 1×
“On the other hand its role in inflammation is not fully clear, since anti- [54] as well as pro-inflammatory [55] effects have been described.”
BackgroundA genome-wide perspective of genetic variation in human metabolism
Illig, T., Gieger, C., Zhai, G., Römisch-Margl, W., Wang-Sattler, R., Prehn, C., Altmaier, E., Kastenmüller, G., Kato, B. S., Mewes, H.-W., et al. (2010) · Nature Genetics · doi:10.1038/ng.507 · Cited by 653
Self-citationAnalysis of the Adult Human Plasma Metabolome
Lawton, K. A., Berger, A., Mitchell, M., Milgram, K. E., Evans, A. M., Guo, L., Hanson, R. W., Kalhan, S. C., Ryals, J. A., & Milburn, M. V. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.4.383 · Cited by 490 · cited 1×
“for the analysis of the adult human plasma metabolome [21] and for the identification of sarcosine as a biomarker for prostate cancer [22].”
BackgroundSerotonin and Depression: A Disconnect between the Advertisements and the Scientific Literature
Lacasse, J. R., & Leo, J. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020392 · Cited by 377 · cited 1×
“Low plasma levels of serotonin were found in depressive patients [26, 27] and depression has been discussed as side-effect of beta-blockers [28].”
Gut microbiome-derived metabolites characterize a peculiar obese urinary metabotype
Calvani, R., Miccheli, A., Capuani, G., Tomassini Miccheli, A., Puccetti, C., Delfini, M., Iaconelli, A., Nanni, G., & Mingrone, G. (2010) · International Journal of Obesity · doi:10.1038/ijo.2010.44 · Cited by 241 · cited 1×
“In addition, 2-hydroxyisobutyrate was reported to be associated with prediagnostic gestational diabetes mellitus conditions [57] and obesity, and it might also be derived from the gut microbiome [58].”
BackgroundBradykinin and des-Arg9-bradykinin metabolic pathways and kinetics of activation of human plasma
Cyr, M., Lepage, Y., Blais, C., Gervais, N., Cugno, M., Rouleau, J.-L., & Adam, A. (2001) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.2001.281.1.h275 · Cited by 160 · cited 1×
“Another substrate of ACE is des-Arg(9)-bradykinin— the active metabolite of bradykinin—which causes blood vessels to dilate [33, 34].”
BackgroundCatecholamine effects on lipolysis and blood flow in human abdominal and femoral adipose tissue
Millet, L., Barbe, P., Lafontan, M., Berlan, M., & Galitzky, J. (1998) · Journal of Applied Physiology · doi:10.1152/jappl.1998.85.1.181 · Cited by 75 · cited 1×
“Since lipolysis is dependent on the action of these hormones, less triglycerides are broken down to free fatty acids [23, 24].”
Background
Cited by
Connecting genetic risk to disease end points through the human blood plasma proteome
Suhre, K., Arnold, M., Bhagwat, A. M., Cotton, R. J., Engelke, R., Raffler, J., Sarwath, H., Thareja, G., Wahl, A., DeLisle, R. K., et al. (2017) · Nature Communications · doi:10.1038/ncomms14357 · Cited by 800
Self-citationSun, Y. V., & Hu, Y.-J. (2016) · Advances in Genetics · doi:10.1016/bs.adgen.2015.11.004 · Cited by 459
“A recent targeted study of 295 metabolites revealed serum effects of antihypertensives and lipid-lowering drugs in an European population (Altmaier et al., 2014).”
BackgroundThe Rotterdam Study: 2016 objectives and design update
Hofman, A., Brusselle, G. G. O., Murad, S. D., van Duijn, C. M., Franco, O. H., Goedegebure, A., Ikram, M. A., Klaver, C. C. W., Nijsten, T. E. C., Peeters, R. P., et al. (2015) · European Journal of Epidemiology · doi:10.1007/s10654-015-0082-x · Cited by 382
Adam, J., Brandmaier, S., Leonhardt, J., Scheerer, M. F., Mohney, R. P., Xu, T., Bi, J., Rotter, M., Troll, M., Chi, S., et al. (2016) · Diabetes · doi:10.2337/db16-0512 · Cited by 68
Self-citation
Metadata
- Authors
- Altmaier, E., Fobo, G., Heier, M., Thorand, B., Meisinger, C., Römisch-Margl, W., Waldenberger, M., Gieger, C., Illig, T., Adamski, J., Suhre, K., & Kastenmüller, G.
- Venue
- European Journal of Epidemiology
- Published
- 2014-05
- Volume
- 29
- Issue
- 5
- Pages
- 325-336
- ISSN
- 0393-2990 (ISSN-L)
- 1573-7284
- OpenAlex
- W1973944357
- Cited by
- 80
- References
- 11
- FWCI
- 3.41
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.